The FDA has also approved Amneal’s generic version of Restasis, cyclosporine ophthalmic emulsion 0.05%, for treating dry eye disease, expected to launch in the first quarter of 2026. 3rd party Ad. Not ...
Please provide your email address to receive an email when new articles are posted on . The sterile, preservative-free formulation is the generic equivalent of Restasis. In patients treated with the ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) on Tuesday announced that the U.S. Food and Drug Administration has approved its cyclosporine ophthalmic emulsion 0.05%, a sterile formulation supplied ...
The FDA approved Amneal's cyclosporine ophthalmic emulsion 0.05%, equivalent to Restasis, for dry eye syndrome, enhancing tear production in specific patients. Amneal's ANDA for bimatoprost ophthalmic ...
BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE ...
Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator indicated to increase tear production in patients with dry eye syndrome. Cyclosporine ophthalmic emulsion 0.05% is a topical ...
‘The combination of the two companies offers big opportunities to the market,’ said PotisEdge founder and president Minjie Shi. Image: PotisEdge. Leading Chinese solar PV manufacturer LONGi has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback